Background: Steady state susceptibility contrast (SSC)-MRI provides information on vascular morphology but is a rarely used method. Purpose: To investigate the utility of the ultrasmall superparamagnetic iron oxide particles (USPIOs) GEH121333 for measuring tumor response to bevacizumab and compare this with gadolinium-based DCE-MRI. Study Type: Prospective preclinical animal model study. ANIMAL MODEL: Mice bearing subcutaneous TOV-21G human ovarian cancer xenografts treated with bevacizumab (n 5 9) or saline (n 5 9). Field Strength/Sequence: Imaging was performed on a 7T Bruker Biospec. For SSC-MRI with GEH121333 we acquired R 1 -maps (RARE-sequence with variable TR), R 2 -maps (multi-spin echo), and R
A ngiogenesis is a hallmark of cancer 1, 2 and essential for tumor growth and formation of metastases. 3 By 1971, angiogenesis was proposed as a therapeutic target for cancer treatment. 4 This was followed by avid research and development of anti-angiogenic drugs such as the anti-vascular endothelial growth factor antibody bevacizumab. 5 However, variable response rates, inherent or acquired resistance and enhanced cancer aggressiveness during treatment have complicated the clinical use of such drugs. 6 The underlying mechanisms of heterogeneous treatment response and resistance remain poorly understood. 7, 8 Validated biomarkers for predicting, characterizing and monitoring treatment response are, therefore, still needed. 8, 9 In parallel with the development of vascular targeting drugs, MRI methods have been developed and used for treatment monitoring. Dynamic contrast-enhanced (DCE)-MRI using gadolinium (Gd)-based contrast agents is used clinically to detect and characterize solid tumors and to assess changes in vascular function during clinical trials of anti-angiogenic treatments. A commonly reported parameter derived from DCE-MRI is the volume transfer constant between plasma and the extracellular extravascular space (K trans ), which has potential for being a predictive biomarker. 9 However, when using low molecular weight contrast agents, this is a composite parameter that depends on blood flow, capillary permeability and capillary surface area. All Gd-based contrast agents approved for clinical use have a molecular weight below 1 kD, 10 which makes it difficult to translate K trans into morphological or functional information. Another MRI method for characterizing tumor blood vessels is steady-state susceptibility contrast (SSC)-MRI, commonly referred to as vessel size imaging. Here, ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, approximately 20 nm or less in diameter, 11 are used as blood pool contrast agents. Characteristics of vascular morphology such as blood volume, vessel size, and vessel density can be derived from the changes in R 2 and R Ã 2 relaxation rates upon USPIO injection. [12] [13] [14] SSC-MRI has mostly been used in preclinical studies. 15 In patients, SSC-MRI has mostly been limited to the brain, and only recently, a clinical study was conducted confirming the feasibility of applying SSC-MRI outside the brain. 16 The rare clinical use of SSC-MRI may be attributed to the unfamiliarity of the method and to the lack of clinically approved iron oxide contrast agents. The latter has led to the off-label use of ferumoxytol, which is indicated for treating iron deficiency in anemia. 17 Another deterrent to widespread clinical use of iron oxide contrast agents may be their strong transverse relaxivity (r 2 ), which results in signal loss in many imaging sequences. Because of this, iron oxides have been generally thought of and used as negative contrast agents. Nevertheless, there is considerable interest in developing new applications for USPIO contrast agents. [18] [19] [20] USPIOs can potentially provide information about tumor vasculature and microenvironment that is complementary to that of low-molecular weight Gd-based contrast agents. In addition, the adverse effect profile of USPIOs is generally different than that of Gd chelates, and USPIOs may, therefore, represent an alternative to Gd-based agents, for example in patients with severely reduced renal function.
In this study, we used the USPIO GEH121333 (GE Healthcare AS, Oslo, Norway), which has so far only been used preclinically. GEH121333 is composed of an Fe 3 O 4 core with a hydroxyphosphonate-polyethylene glycol (PEG) shell (US patents 9,205,155 and 9,474,810). It has an average hydrodynamic diameter of 22 nm, a longer blood halflife than ferumoxytol and a relatively low ratio of r 2 to the longitudinal relaxivity (r 1 ) compared with other USPIOs, making it feasible to generate positive contrast (i.e., signal enhancement). 20 The aims of this study were to evaluate the performance of GEH121333 particles as an SSC-MRI contrast agent in a murine xenograft model, and to test whether their T 1 shortening properties can provide additional information about tumor vasculature.
Methods

Relaxivity Measurement
The r 1 and r 2 relaxivities of GEH121333 were measured at 7T on a Bruker Biospec (Bruker Biospin, Ettlingen, Germany) with a 72-mm volume resonator for RF transmission and reception. Seven Eppendorf tubes were filled with GEH121333 diluted in saline to concentrations between 0.0014 mg Fe/mL (0.025 mM) and 0.14 mg Fe/mL ( 5 2.51 mM) and inserted into a water filled phantom holder. R 1 was measured using a rapid acquisition with relaxation enhancement sequence with variable repetition times (RARE-VTR) with an effective echo time (TE eff ) 5 7.5 ms, repetition time (TR) 5 200, 250, 300, 500, 1000, 2000, 5000, 10,000 ms, RARE factor 5 2. R 2 was measured using a multi-spin echo (MSE) sequence with TE 5 7 ms, echo spacing 5 7 ms, 40 echoes, TR 5 3 000 ms. The relaxivities were then computed as the slope of the regression line of R 1,2 versus GEH121333 concentration.
Tumor Model and Bevacizumab Treatment
An overview of the timeline of the in vivo experiments is presented in Figure 1 . All experimental procedures involving animals were approved by The National Animal Research Authority and carried out according to the European Convention for the Protection of Vertebrates used for Scientific Purposes.
The human ovarian cancer cell line TOV-21G (ATCC CRL-11730) was purchased directly from ATCC (Manassas, VA). The cells were grown in a 1:1 mixture of Medium 199 (41150; Gibco, Life Technologies, Oslo, Norway) and MCDB 105 Medium (M6395; Sigma-Aldrich, Oslo, Norway) supplemented with 15% fetal bovine serum and 0.05 mg/mL Gentamicin under sterile conditions in 5% CO 2 and 95% air at 37 8C and used before they reached 20 passages.
Female athymic BalbC nu/nu mice (Taconic Tornbjerg, Ejby, Denmark) were inoculated subcutaneously on the hind limb with 5 3 10 6 TOV-21G cells in phosphate buffered saline with 1% fetal bovine serum. After 4-5 weeks postinoculation, when the tumors had reached an average size of 0.34 cm 3 6 0.11 cm 3 , the mice were randomized into treatment and control groups. The mice in the treatment group (n 5 9) received 5 mg/kg bevacizumab (Avastin, Roche, Switzerland) in saline i.p. on day 0 right after MRI and on day 3 of the experiments. The control group (n 5 9) received an equal volume of saline. Two additional mice did not receive treatment but their tumor longitudinal relaxation rates (R 1 ) values were measured using MRI before and at several time points (i.e., 0.5, 24, 48, 72, and 96 h) after GEH121333 injection to estimate the accumulation and clearance characteristics of the contrast agent in the tumor.
In Vivo MRI and Data Analysis
In vivo MRI was performed on the same 7T Biospec with an 86-mm volume resonator for RF transmission and a four-channel array mouse brain surface coil for reception. The mice were anesthetized with isoflurane ($2% in 67% air and 33% O 2 ) during imaging; isoflurane levels were adjusted as needed to maintain the respiration rate at $60 breaths/min. The body temperature was maintained at 37 8C by circulating warm water.
Anatomical imaging and T 1 , T 2 , and T The previously created tumor regions of interest (ROIs) were downsampled to match the resolution of the relaxation maps and a three-voxel-wide ($1 mm) tumor rim was automatically extracted to exclude the frequently poorly vascularized tumor center. Parameter medians were computed for these tumor rims for statistical analysis.
3D VOLUME DETERMINATION. The 3D tumor volume was assessed on days 0 and 5 before iron oxide injection using a 3D RARE sequence for which a cubic field of view with 2 cm lateral length completely included the tumor mass. The sequence parameters were TE eff 5 45 ms, RARE factor 5 16, TR 5 1 s, NA 5 1, MTX 5 64 3 64 3 48, acquisition time 5 1 min 48 s. Tumor ROIs were annotated manually in the images by JK (6 years of experience with MR imaging of subcutaneous tumor xenografts) from which the total tumor volume was calculated .
DCE-MRI.
On treatment day 6 after all other sequences were acquired, DCE-MRI was performed by acquiring a series of 200 T 1 weighted images using a RARE sequence with the same geometry (field of view 5 The DCE-MRI data were analyzed as described in a prior study. 21 Only voxels with at least 50% enhancement after 1 min were considered. The relative signal increase after 1 min (RSI 1min ), the area under the enhacement curve after 1 min (AUC 1min ), time to peak (TTP), and the extended Tofts model parameters -volume transfer constant (K trans ), extravascular, extracellular space (v e ), flux rate constant (k ep 5 k trans /v e ), and blood plasma volume fraction (v p ) -were calculated from the enhancement curves, T 1 maps, and a population-based vascular input function. 22 
Histology
After DCE-MRI, the mice were killed by cervical dislocation, and the tumors were excised and fixed in 4% formaldehyde. Sections of 4 lm thickness were stained with anti-a-smooth muscle actin (monoclonal mouse anti-human a-SMA; DAKO, Glostrup, Denmark) as a pericyte marker and counterstained with hematoxylin. Alpha-SMA is a marker for pericytes, which are present on most tumor vessels, 23 and the fraction of a-SMA stained tumor area was used as a substitute marker for tumor blood volume.
On an Olympus BX41 microscope, five nonoverlapping random fields across the viable regions of one section per tumor were acquired at 20 3 magnification while blinded to the experimental groups. These images were saved as RGB TIFF files. Using a custom MATLAB script, the RGB images were converted to the CIE-LAB color space, and a manually determined set of thresholds was used to segment the a-SMA areas and compute the a-SMA area fraction.
Statistics
Paired-sample t-tests were performed in SPSS Version 24 (IBM) to test for significant changes in SSC-parameters from day 0 to day 5. Independent sample t-tests were performed to compare DCEand SSC-parameters for control versus treated groups with a significance level P < 0.05.
To evaluate how well SSC-and/or DCE-MRI parameters can distinguish treated from control tumors, multivariate partial least squares-discriminant analysis (PLS-DA) 24 was performed.
PLS-DA classification models were built in Matlab R2013b (The Mathworks, Inc., Natick, MA) using PLS Toolbox 7.8.2 (Eigenvector Research Inc., Wenatchee, WA). We used the posttreatment day 5 SSC-parameters, the day 6 DCE-parameters, or a combination of both, to build models for discriminating treated animals from untreated controls. The training data were autoscaled before PLS-DA model building. Variable selection was performed using variable importance in projection (VIP). 25 Parameters with VIP 1 can be considered unimportant for the classification and were excluded. 26 Parameters selected as important (VIP > 1) were used in a further model. Double-layered cross-validation (CV) 27 was used to optimize the number of PLS latent variables and to assess model performance to avoid overfitting the models. For this, 20% of the samples were left out at each testing round. Classification model assessment parameters considered were classification accuracy, sensitivity and specificity. In addition, permutation testing 27 was performed by building PLS-DA models after randomly shuffling (permuting) the class labels of treated or untreated control for each animal 1000 times. Permuted models were assessed similarly, using single layered CV. Models were considered significant if the final accuracy obtained from nonpermuted double CV was higher than 95% of the permuted accuracy values (P 0.05).
Correlations between R 1 and R 2 or DR 1 and DR 2 after GEH121333 injection were computed voxelwise for each tumor and the mean Pearson correlation coefficients are reported. In addition, the correlation between tumor median R 1 and R 2 or DR 1 and DR 2 were computed.
Results
Tumor Volume was not Influenced by Treatment
Both treated and control groups showed an increase in tumor volume from day 0 (control, 0.33 6 0.12 cm ; treated, 0.53 6 0.15 cm 3 ) (P < 0.001, paired sample t-test of absolute volume). There was no significant difference in absolute volume change between the two groups (P 5 0.83, independent sample t-test).
GEH121333 Relaxivities and Tumor Retention
Before the start of the treatment study we characterized the relaxivities of GEH121333 in vitro and its longitudinal retention in the tumor. At 7T and room temperature, the relaxivities were measured as r 1 . Longitudinal R 1 mapping over the course of 4 days showed that there was a high concentration of GEH121333 in the tumor 1 day after administration, but that the signal in the tumor returned to baseline after approximately 3 days (Fig. 2) . For blood vessel characterization, we, therefore, waited 5 days between GEH121333 injections to allow for normalization of the tissue relaxation rates. 
MRI Using Iron Oxide Nanoparticles Visualizes Early and Late Morphologic Changes in Tumor Vasculature
The absolute values and the changes of the SSC-parameters are displayed in Figure 3a and Table 1 , respectively. There was a significant decrease in median DR 2 and DR Ã 2 in treated tumors, which translated to a significant decrease also in median Q. Median R increased, but not significantly more than in the control group. Histology confirmed the reduced vascularization in treated tumors. The a-SMA area fraction decreased, indicating a lower blood volume, and the images show a decrease in vessel density (Fig. 3c,d ).
R 2 was also measured on the day after GEH121333 injection ( Fig. 3d) . Generally, R 2 increased after contrast agent injection as expected and returned to baseline by day 5. The second contrast agent injection led to a very similar increase in R 2 for the control group. For the treatment group, this increase was significantly lower both from day 5 pre to day 5 post (P 5 0.022) and from day 5 post to day 6 (P 5 0.014). Of interest, already on day 1, the treatment group showed a significantly lower R 2 than the control group (P 5 0.014), although bevacizumab was administered approximately 30 min after GEH121333 injection on day 0. GEH121333 injection was performed on days 0 and 5. Differences in R 2 and R 1 between treated and control groups were assessed using an independent sample t-test for single time points and for changes between consecutive timepoints: *P < 0.05, **P < 0.005.
GEH121333-Induced Changes in R 1 Correlate with Changes in R 2
The longitudinal development of R 1 shows strong similarities to the development of R 2 (Fig. 3d,e) . The most conspicuous difference is the relatively strong initial increase in R 1 immediately following USPIO injection compared with a relatively low initial increase in R 2. Both tumor rim median DR 1 and DR 2 and median R 1 and R 2 values were correlated as shown in Figure 4 . The median tumor rim DR 1 and DR 2 showed very strong linear correlations both on day 0 and 5, and median tumor rim R 1 and R 2 showed strong linear correlations on the days after contrast agent injection (day 1 and 6). For most tumors, also the voxelwise DR 1 and DR 2 were well correlated, as were R 1 and R 2 on the days after contrast agent injection (Table 2) . Visually, both the T 1 -weighted (positive contrast) and T 2 -weighted (negative contrast) images demonstrate the uptake of GEH121333 (Fig. 5) .
DCE MRI Demonstrates Treatment-Induced Changes in Vascular Function
DCE-MRI was performed as the last imaging protocol to verify differences in the tumor vasculature between treated and control groups. Several parameters were significantly reduced for treated compared with control tumors including the AUC 1min (P 5 0.040), K trans (P 5 0.002), k ep (P 5 0.005), and v p (P 5 0.024), while TTP increased significantly (P 5 0.001) for the treated tumors. This indicates a decrease in perfusion, vessel permeability and/or vascular volume in the treated tumors (Fig. 6) .
Comparison of Classification of Treated and Control Groups with DCE-and SSC-MRI
The results from PLS-DA classification to discriminate treated animals from untreated controls are summarized in Table 3 . Parameters selected as important for the discrimination (VIP > 1) were Q, DR 1 and DR 2 for SSC-MRI and TTP, K trans , v p and k ep for DCE-MRI (Table 4 ). These parameters were selected when combining the data from both modalities to build a single PLS-DA model. The SSC-MRI model performance improved when including only selected parameters, approaching significance. Performance of the DCE-MRI model was unchanged when including only selected parameters. In both cases, the model combining SSC and DCE parameters was superior to individual methods.
Discussion
In this study, we investigated the effects of bevacizumab on the vasculature of subcutaneous ovarian cancer xenografts with SSC-and DCE-MRI and compared the performance of these two methods with regard to how well they distinguish treated from untreated tumors. In addition, we were interested in the T 1 shortening properties of GEH121333 compared with its T 2 shortening abilities. The response of the ovarian tumors to bevacizumab was mostly in agreement with other clinical and preclinical data. SSC-MRI derived microvascular and macrovascular blood volume and vessel density were significantly reduced as frequently reported. 28 The reduced vascularization was corroborated by histology. While vessel size was slightly increased, most studies report a decrease in vessel diameter, 28 although this was not observed in all studies. 29 For DCE-MRI, the results indicate that treatment resulted in decreased tumor perfusion and vessel permeability. This is in agreement with other studies, where, e.g., K trans is typically reduced after anti-angiogenic treatment.
30
Also DCE-MRI indicates a decrease in tumor blood volume, measured as a decrease in v p . Like shown previously, 20,31 the strongest R 1 and R 2 effects were measured approximately 24 h after USPIO injection, suggesting extravasation and accumulation of the nanoparticles in the tumors. While USPIOs have been shown to accumulate in macrophages, R 1 effects are stronger for extracellular iron. 31 The R 1 enhancement measured in this study suggests that USPIOs mostly accumulated by means of the enhanced permeability and retention (EPR) effect in the extracellular space. Because R 1 and R 2 changes were reduced in treated mice, USPIO accumulation was lower in treated mice, which may be attributable to a decrease in permeability. The half-life of GEH121333 in the blood has been measured to be approximately 4 h in rats. 20 In our study, bevacizumab
was administered approximately 30 min after GEH121333, which suggests that vascular permeability decreased over a period of hours after treatment, while a considerable amount of USPIOs was still present in the blood. This is also in line with other studies showing that changes in the tumor Negative DR 1 and DR 2 values were excluded from the analysis. Positive fraction was 0.82 6 0.14 (mean 6 SD).
FIGURE 5: MR-images from all imaging timepoints for one representative control tumor. Note that the tumor is the center of the image and appears bright in the high resolution image, while the muscle on the top right appears dark. T1w: TE eff 5 13 ms, TR 5 500 ms; T2w: TE 5 73.5 ms, TR 5 3000 ms; T2*w: TE 5 15 ms, TR 5 2000 ms. For reference purposes, the image window was identical for each timepoint, although the signal intensity can also be influenced by variations in the setup on the various days (e.g., coil positioning and shimming).
vasculature, especially in permeability, happen as early as 1 h after treatment with bevacizumab. 32 Only few other studies combine Gd-based DCE-MRI and USPIO-based SSC-MRI to evaluate drugs targeting tumor vasculature. 29, 33, 34 Like this present study, these studies showed that vascular targeting drugs can affect both vascular function and morphology and that it can be useful to report both to get a complete picture of how a specific drug affects the tumor vasculature. This was also emphasized by a recent study that described how DCE-MRI can be strongly influenced by vascular structure and that anti-angiogenic treatment can alter the correlation between vascular function and structure. 35 Obtaining comprehensive data on various aspects of the tumor vasculature may, therefore, be crucial for the development of anti-vascular drugs and strategies for monitoring response to such drugs in the clinic. Our multivariate analysis illustrated the benefit of multiparametric imaging, showing that the combination of SSC- MRI and DCE-MRI better distinguished treated from control tumors than either modality alone. It was possible to increase performance by including only selected variables in the PLS model. For SSC-MRI, the specificity increased when excluding DR2* and R, with the latter not being significantly different between treated and control groups based on univariate ttest. Of interest, for DCE-MRI, the sensitivity was increased but the specificity decreased when only using selected variables. Though the biological interpretation of these findings is not straightforward, they emphasize the importance of identifying the most relevant biomarkers for a specific combination of disease type and treatment regimen. Due to the lack of suitable clinically approved contrast agents, relatively few clinical studies have been conducted with SSC-MRI compared with DCE-MRI. But because SSC-MRI gives useful complimentary information to DCE-MRI through a comparably simpler acquisition protocol, it is a highly translational and reproducible method worth exploring further. The following paragraphs address some of the disadvantages of USPIOS and how they can be circumvented as illustrated by the present and previous studies.
In general, USPIOs are well tolerated and can be expected to provide a different adverse reaction profile compared with Gd-based contrast agents, especially for patients with reduced renal function. In particular, the USPIO ferumoxytol has been used in many diagnostic imaging studies. 36 In some rare cases, however, severe adverse effects such as anaphylactoid reactions have been reported, which occurred when injecting ferumoxytol as a bolus in therapeutic doses (U.S. Food and Drug Administration [FDA]). 2 These reports have led the FDA to release new guidelines calling for slow infusion, which has cast uncertainty on the future clinical role of USPIOs as contrast agents, especially in applications like SSC-MRI that require bolus administration. However, imaging doses are typically lower than the therapeutic dose, and preliminary safety studies indicate that the benefits will likely exceed the risks for many patient groups. 36 Furthermore, there are applications of USPIO contrast-enhanced MRI that do not require bolus administration and adhere to current guidelines. One is the detection of lymph node metastases in images acquired 1 day after USPIO administration. This has shown success in breast cancer 37 and prostate cancer. 38 Our data indicated that R 1 and R 2 measurements 1 day after USPIO injection can also be useful for characterizing primary tumors, a potential that should be investigated further, especially because it would allow to combine primary cancer detection and characterization with lymph node imaging using a single dose of contrast agent. A perceived drawback of USPIOs is that they have a much higher r 2 than r 1 , which makes them mostly suitable as negative contrast agents (shortening T 2 and T Ã 2 ). The two SPIOs ferumoxide and ferumoxtran, indicated for liver imaging but no longer marketed, were reported to have r 2 / r 1 ratios of 8.7 and 7.0 at 1.5 T, respectively, and 45.7 and 62.9 at 4.7T, respectively, (at 37 C). 39 Ferumoxytol has an r 2 /r 1 of 5.9 at 1.5T and 37 C. 40 For comparison, clinical gadolinium-based contrast agents have an r 2 /r 1 of around 1.1-1.2 at 1.5T and 37 C. 39 However, lower r 2 /r 1 ratios have been achieved for newer generations of USPIOS like GEH121333, which has an r 2 /r 1 of 2.4 at 1.5 T (at 40 C), 20 and in our study we measured an r 2 /r 1 of 15.1 at 7T (at 20 C). As we demonstrate here, this makes it feasible to use GEH121333 as a T 1 contrast agent.
For vascular imaging with USPIOs, the T 1 effects are rarely reported. Several groups have used ferumoxytol as an R 1 contrast agent for MR angiography in patients. [41] [42] [43] However, we are unaware of reports of tissue R 1 values in connection with vascular imaging and treatment monitoring using USPIOs. In this study, we observed a strong correlation between changes in tumor R 1 and R 2, , and DR 1 could differentiate treatment from control groups. This could indicate that DR 1 may be usable as a surrogate marker for vascular volume, e.g., when R 2 measurements are noisy.
The main limitation of the study is that SSC-and DCE-MRI were not performed in the same scanning session. Hence, the ROIs were not identical and also no voxelwise comparison was possible. In addition, the lack of Another limitation of the study was the use of a population-based vascular input function for DCE-MRI, which gives less accurate results than individual vascular input functions.
In conclusion, this study highlights the potential of SSC-MRI for treatment response evaluation. While SSC-MRI was slightly inferior to DCE-MRI when it came to distinguishing bevacizumab-treated from control tumors, we demonstrated that (i) SSC-MRI is sensitive to bevacizumabinduced changes in tumor vasculature, (ii) USPIOs can be used to characterize early changes ( < 24 h) in tumor vasculature, and (iii) USPIO-induced changes in R 1 correlate with changes in R 2 , indicating that GEH121333 may be useful also as a positive contrast agent. While there are still challenges to the adoption of USPIOs for routine clinical use, developing USPIO nanoparticles with more desirable relaxivity profiles like GEH121333 will increase their potential for clinical translation.
